Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy (Q80605220)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 July 2007

Language	Label	Description	Also known as
English	Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy	scientific article published on 01 July 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

author name string

Silvia Romero

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Gail Stanton

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Joseph DeFelice

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Fred Schreiber

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Randy Rago

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Mayer Fishman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

284-290

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin‐6

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Thalidomid: current role in the treatment of non-plasma cell malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Current status of thalidomide and its role in the treatment of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

The use of thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.09.017

7 January 2021

Identifiers

10.1016/J.UROLONC.2006.09.017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17628293%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80605220&oldid=1368852951"